

Learner Notification

World Federation of Societies of Biological Psychiatry

Early Interventions in Major Mental Disorders

Date of CE Release: August 15, 2024

Date of CE Expiration: August 15, 2025

Location: Online

Acknowledgement of Financial Commercial Support

Sumitomo Pharma Co., Ltd.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and World Federation of Societies of Biological Psychiatry. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163

Physicians

Amedco LLC designates this material for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After Attending This Program You Should Be Able To

1. Understand the concept and approaches of early intervention.
2. Evaluate the effectiveness of early intervention in mental health outcomes.
3. Examine the impact of early intervention on disease trajectory and clinical outcomes.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Michael Berk	NA
Peter Falkai	Boehringer-Ingelheim:Consultant
Sarah Jacobs	NA
Kent Prickett	NA
Tracy Sandstrom	NA
Jai Shah	NA
Lakshmi Yatham	Sumitomo Pharma:Research Grant Site Principal Investigator Sumitomo Pharma, Abbvie, Merck, Alkermes, Lundbeck Foundation:Consultant Intracellular Therapies:Corporate Board Member Sanofi:Speakers Bureau
Alison Yung	Seqirus:Other